Clinical Trials

The aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, coordination and collaboration between multiple centers will help our understanding of disease manifestations, course, and complications, with the aim of improving future care, expanding clinical and translational research, and finding an eventual cure for individuals with EB.

Volunteers are needed for a study on the microbiome of subjects with and without vitiligo. For patients with vitiligo and without vitiligo, the study will include an initial visit, at which time samples of the skin and swab samples of stool will be collected. All subjects will be asked to complete questionnaires about their skin care regimen and dietary habits.

The purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these diseases and how they are treated. A patient registry is a collection of information about a group of patients who share a condition or experience.

Additionally, researchers are interested in:

• Observing how skin condition treatments work and understand side effects caused by these medicines and how these are managed
• Identifying other types of conditions associated with skin disorders
• Collecting patient reported outcomes to better understand the patient perspective and feelings patients have about having a skin condition
• Assessing the impact of Patient Support Programs for individuals with skin conditions and how these programs affect skin condition outcomes
• Creating a “Biorepository Specimen Bank” with blood and saliva samples

The purpose of this study is to better characterize and understand the spectrum of skin disease evaluated in the inpatient hospital setting.

The purpose of this study is to determine the highest dose of the study drug that can be given safely to patients with pemphigus vulgaris. The study will test how the study drug affects desmoglein 3 (DSG3) autoantibody amounts in your body. DSG3 is responsible for holding together the cells lining the inside of the mouth, nose, throat, eyelids and genitals, causing the painful blisters commonly seen in patients with pemphigus vulgaris. The study will also look at how long the study drug stays in your body, and if the study drug improves the symptoms that you are experiencing with the pemphigus vulgaris.

This study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your blood, if any. The efficacy, how well the study drug works, will also be evaluated.

This research is being done to determine the impact of dupilumab on sleep in children suffering from AD. Dupilumab is an FDA approved drug that can improve your eczema, and is injected under the skin once every other week for patients weighing more than 30kg (about 66 lbs) or once a month for patients weighing less than 30kg (about 66 lbs).

If you agree to take part in the study, you will complete a screening visit at a Lurie Children’s location, NMH, or Abbott Hall after which you will come to Lurie Children’s Hospital, NMH, or Abbott Hall for two scheduled overnight stays where sleep studies will be performed. The screening visit may be completed remotely, and a watch to be used in this study will be mailed to your address. The study drug will first be given at the end of the pre-treatment visit. During the pre-treatment study visit, you will be trained on how to inject the study drug at home.

During weeks 1-12, you will continue injections of the study drug at home. Your study doctor or staff may contact you virtually during this period to check-in.

This research is being done to determine the impact of dupilumab on itch in children and adults suffering from itch disorders. Dupilumab is an FDA approved drug for eczema. Dupilumab is injected under the skin once every other week for patients weighing more than 30kg (about 66 lbs.) or once a month for patients weighing less than 30kg (about 66 lbs.).

We expect that your child will be in this research study for about 2 years (26 months, or 104 weeks). There will be an observational period of 8 weeks, followed by a treatment period of 16 weeks in which your child will receive dupilumab. This may be followed by a 20-month long-term extension period for those who qualify and wish to continue.

Your child will attend up to seven (7) visits in person during the observation period and 16-week open label phase period. The screening visit will take approximately 3 hours, and all other in person visits will take approximately 1-2 hours to complete.

As the number of available treatments for CTCL grow, there is a need to find a way to identify which treatment will work best for each subject. The goal of this study is to develop a test called a gene expression assay to see if the assay can predict treatment success and/or failure in subjects with CTCL.

The primary aim of this study is to assess the safety and efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) mycosis fungoides (MF). Subjects will be asked to use the imiquimod cream at designated lesions nightly for 5 consecutive days a week over 6 weeks. One week into the imiquimod treatment course, radiation therapy will be administered at Northwestern Medicine by radiation oncologists familiar with radiation treatment in 2 fractions of 4 Gy (units of radiation absorbed by the patient) (total 8 Gy) over 2 days to the same designated lesions. In addition, subjects will have two skin biopsies during the screening period and again at the same locations at week 8.

The purpose of this study is to collect characteristic data from patients with medical conditions affecting hair health using medical records and surveys.

The main benefit of being in this study is to provide future benefit to patients with acquired and congenital hair disorders and the providers who care for them by adding to our understanding of normal hair physiology, causes and mechanisms of disease, clinical and molecular features, natural history, and treatment outcomes.

This research is being done to test the safety and efficacy of the study drug, upadacitinib, compared to a placebo (a treatment with no active properties) for the treatment of HS patients. Upadacitinib has been approved for specific medical conditions, but not approved for HS. The use of the study drug is investigational (experimental) for the purposes of this study.

This research is being done to test the safety and efficacy of the study drug, upadacitinib, compared to a placebo (a treatment with no active properties) for the treatment of alopecia areata patients. Upadacitinib has been approved for specific medical conditions, but not approved for AA. The use of the study drug is investigational (experimental) for the purposes of this study.

Povorcitinib is an investigational drug that is being studied for use in the treatment of hidradenitis suppurativa . The purpose of this study is to compare the safety and effects of INCB054707 compared to a placebo in people with hidradenitis suppurativa (HS). We expect that you will be in this research study for about 14 months or 62 weeks. You will be expected to make about 15 visits to the study site.